Lipid Lowering Therapy with Combination of Niacin and Statin in Women: Age-Related Endothelial Effects
Table 1
Clinical characteristics and medications, by intervention group*.
Variables (visit)
Category
Niacin plus statin group
Placebo plus statin group
value
Age (yr)
Mean (SD)
67.73 (11.27)
65.62 (6.40)
0.45
Median
68.50
66.00
Completed study
Yes
16 (72.73)
20 (95.24)
0.10
No
6 (27.27)
1 (4.76)
Relatives with CHD
Yes
11 (55)
9 (50)
0.76
No
9 (45)
9 (50)
High blood pressure (ever told)
Entry (visit 2)
Yes
15 (68.2)
12 (57.1)
0.45
No
7 (31.8)
9 (42.9)
Diabetes (ever told)
Entry (visit 2)
Yes
2 (9.1)
1 (5.0)
1.00
No
20 (90.9)
19 (95.0)
Stroke
Yes
2 (9.1)
1 (4.76)
1.00
No
20 (90.9)
20 (95.24)
Smoking
Current
1 (4.5)
2 (9.52)
0.24
Past
7 (31.82)
11 (52.38)
Never
14 (63.64)
8 (38.10)
Unless otherwise indicated, data are expressed as number (percentage of treatment population).
*For the niacin group , placebo group = 21, at entry. Six patients in the niacin group and 1 patient in the placebo group did not complete the study. Yr: years; SD: standard deviation; CHD: coronary heart disease; value represents between-group comparison.
